Idorsia Pharmaceuticals
As of the edition of 20 October 2026, Idorsia Pharmaceuticals runs 24 drugs, 3 of them marketed; it is on route A at 1 target and on route B at 3 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 3 |
| Active | 4 |
| Went quiet | 12 |
| Stopped | 4 |
| Status not established | 1 |
| Total | 24 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Daridorexant | Ends 2034 (patent) | 4 |
| Aprocitentan | Ends 2038 (patent) | 3 |
| Clazosentan | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 1 target, route B at 3 targets.
All 4 rows on route A or B
In the product4 company-target rows on route A or B; 1 is not shown here, and no score is.
See all 4 targets where Idorsia Pharmaceuticals needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Nervous system: 21 trials led
- Heart and blood vessels: 14 trials led
- Mental health: 11 trials led